Journal of Cardiovascular Disease Research
Patients with heart failure and reduced ejection fraction after sacubitril/valsartan treatment may be at risk for major adverse cardiovascular events according to ΔRDW.
Shashi Bhusan Sutar, Jitendra Naik, Gouri Oram, Desabandhu Behera
JCDR. 2024: 601-608
Abstract
The objective of this study was to assess the correlation between alterations in the distribution width of red blood cells (RDW) and the incidence of major adverse cardiovascular events (MACEs) in patients with heart failure with reduced ejection fraction (HFRF) receiving sacubitril/valsartan therapy
» PDF